10.6084/m9.figshare.7981019.v1 Ke Xu Ke Xu Dongkyoo Park Dongkyoo Park Andrew Magis Andrew Magis Jun Zhang Jun Zhang Wei Zhou Wei Zhou Gabriel Sica Gabriel Sica Suresh Ramalingam Suresh Ramalingam Walter Curran Walter Curran Xingming Deng Xingming Deng Additional file 7: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy Springer Nature 2019 KRAS Agonist Apoptosis Autophagy NSCLC Therapy 2019-04-10 05:00:00 Figure https://springernature.figshare.com/articles/figure/Additional_file_7_of_Small_Molecule_KRAS_Agonist_for_Mutant_KRAS_Cancer_Therapy/7981019 Figure S7. Determination of single dose maximum tolerated dose (MTD). (A) Nu/Nu nude mice were treated with single dose (i.e. 0, 150 mg/kg, 300 mg/kg or 400 mg/kg) KRA-533 via i.p. (n = 6 mice per group). After treatment, the body weight of mice was measured once every other day for 2 weeks. (B) Blood analysis of mice after treatment with single dose(s) of KRA-533. (C) H&E histology of various organs from mice after treatment with single dose(s) of KRA-533. (JPG 1446 kb)